GC Pharma receives nod in Japan for Hunterase

Home > Business > Industry

print dictionary print

GC Pharma receives nod in Japan for Hunterase

GC Pharma said Wednesday that Clinigen, its Tokyo-based partner, applied for sales approval in Japan for its Hunter syndrome treatment candidate.

Hunterase ICV earned categorization as a treatment option for unmet medical needs, GC Pharma said. At the moment, there is no known cure for Hunter Syndrome, which is characterized by skeletal, tissue, neurological and multi-organ complications resulting from a lack of certain enzymes.

The inherited lysosomal storage disease occurs in around 1.3 out of 100,000 male newborns.

Clinigen signed an exclusive licensing agreement in Japan for GC Pharma’s candidate therapy last year.

According to GC Pharma, Hunterase ICV showed in clinical trials that the amount of heparin sulfate, a primary substance responsible for the disease, was significantly reduced, and development disorder symptoms were alleviated.

By Ko Jun-tae
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)